5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes. [electronic resource]
Producer: 20191108Description: 2835-2843 p. digitalISSN:- 1432-1335
- Aged
- Antimetabolites, Antineoplastic -- pharmacology
- Azacitidine -- pharmacology
- Biomarkers, Tumor -- genetics
- Case-Control Studies
- CpG Islands
- DNA Methylation
- Enhancer of Zeste Homolog 2 Protein -- genetics
- Female
- Follow-Up Studies
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Leukemia, Myelomonocytic, Chronic -- drug therapy
- Male
- Middle Aged
- Myelodysplastic Syndromes -- drug therapy
- Prognosis
- Receptor, Notch1 -- genetics
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.